For example, in preclinical studies, pH‐responsive exosome‐nanocouples have been developed by modifying the surface of M1 macrophage‐secreted exosomes with anti‐CD47 and anti‐SIRPα antibodies through acid‐cleavable of dibenzoylethylene bonds, targeting tumor cells. Here, CD47 is linked to neoplasm.